HLA DQ2/DQ8 haplotypes and anti-transglutaminase antibodies as celiac disease markers in a pediatric population with type 1 diabetes mellitus

Objective

Evaluate the celiac disease (CD) markers, within the scope of its screening, in a pediatric population with diagnosis of type 1 diabetes (T1D) at Hospital de Braga (HB) and determine the prevalence of CD in the sample. Reflect on CD screening algorithm applied in this pediatric population.

Methods

Retrospective observational study with 94 patients diagnosed with T1D at age 10 years or younger, followed up at the HB Outpatient Diabetology Consultation, including those referred from other hospitals. Record of clinical information, IgA anti-transglutaminase and anti-endomysium and HLA DQ2/DQ8 haplotypes.

Results

We obtained positive serological test for CD in 4 patients. This test had 100% sensitivity and specificity. The prevalence of CD was 4.3% (n = 4). Positive HLA screening in 84.6% of patients, with both sensitivity and negative predictive value of 100% and specificity of 16.67%. Diagnosis of CD was made on average 3.40 ± 3.32 years after the diagnosis of TD1. All cases of CD registered non-gastrointestinal manifestations, none had gastrointestinal symptoms.

Conclusion

This study proved that there is a higher prevalence of CD in pediatric population with TD1, when compared to general population, and clarified the importance of CD screening. Furthermore, it was observed that serological screening for CD antibodies is an excellent screening test and HLA typing, although not the most suitable first line test, can be useful in excluding the possibility of patients with T1D developing CD.

Genetic atypical hemolytic uremic syndrome in children: a 20-year experience from a tertiary center

Introduction:

Atypical hemolytic uremic syndrome (aHUS) is a rare disorder characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury, which primarily affects preschool-aged children. This study’s aim was to describe the clinical profile, management, and long-term outcome of the genetic aHUS patients admitted to a tertiary care pediatric nephrology center during 20 years.

Methods:

We performed a retrospective analysis of the clinical records of all aHUS patients younger than 18 years with identified genetic mutations. Data on clinical features, genetic study, therapeutic interventions, and long-term outcomes were reviewed.

Results:

Five cases of aHUS with an identified genetic mutation were included; all were inaugural cases with the youngest being 4 months old. Complement factor H gene mutation was identified in four patients. Therapeutic plasma exchange was performed for acute management in 4 patients, one of whom also needed acute renal replacement therapy (peritoneal dialysis). All patients went on complete remission, 2 had more than one relapse but only 1 of these progressed to chronic kidney disease during the follow-up period (median (25th-75th percentile), 136 (43.5-200.5) months).

Conclusion:

In children, the prognosis of renal function seems to be strongly dependent on the genetic background, thus being crucial to perform genetic study in all aHUS cases. In our cohort, 2 patients presented genetic mutations not previously described. Recent innovations on the genetic field leading to the identification of new mutations has lead to a better understanding of aHUS pathogenesis, but further studies, focusing on the genotype-phenotype correlation, with longer follow-up periods, are needed.

Follow-up of infants born to mothers with Graves' disease

INTRODUCTION

The prevalence of neonatal hyperthyroidism (HN) due to maternal Graves Disease (GD) ranges from 0.1 to 2.7%. It may occur in pregnant women with the following: active DG, after treatment with radioactive iodine, anti-thyroid or thyroidectomy or with a previous child with hyperthyroidism. The aim of our observational study was to evaluate the follow-up of infants born to mothers with GD at a Tertiary Hospital prior to the implementation of a follow-up protocol.

METHODS

This was a retrospective observational study using data from the medical records of mothers with a diagnosis of GD and their newborns from January 2013 until May 2018. Newborns were divided into two groups: high and low risk for NH according to maternal TRAb, third trimester treatment and signs of fetal hyperthyroidism.

RESULTS

We identified 31 newborns, 58% female; 87% high risk. In none of the newborns was umbilical cord blood collected. In the high risk group, 22% had thyroid function evaluation at day-1, one patient presented with hyperthyroidism and 82% were asymptomatic. Considering the cases with an insufficient blood sample for analysis, 9 consultations would have been spared. We found a significant delay in obtaining the high-risk group results which would have spared 10 appointments. A positive correlation was found between age at outpatient clinic discharge and the number of appointments and the maternal TRAb titer.

CONCLUSION

The correct surveillance of pregnancy and newborns with identification of those at high risk is essential to avoid unnecessary consultations and blood analyses that increase parental anxiety and hospital costs. Consequently, a multidisciplinary protocol was created to standardize the approach.

Infeção Nosocomial Relacionada com Cateteres Centrais em Unidade de Cuidados Intensivos Neonatais: Estudo Prospetivo

INTRODUÇÃO: Os acessos intravasculares são indispensáveis nas unidades de cuidados intensivos neonatais (UCIN) nível III. A monitorização das taxas de infeção é considerada um importante indicador dos cuidados de saúde. O objetivo deste estudoé determinar a incidência atual de infeção associada ao uso de cateter central (CC), comparar os resultados com outras publicações e com um estudo prévio realizado na nossa unidade em 2011.MÉTODOS: Estudo prospetivo realizado de janeiro de 2017 a dezembro de 2019 na UCIN do Hospital de Braga. Incluídos todos os recém-nascidos (RN) com CC colocado na nossa unidade. O diagnóstico microbiológico foi efetuado através de colheita de hemocultura e cultura da ponta do CC.RESULTADOS: Foram colocados 404 CC no total, 138 cateteres umbilicais (CU) e 266 cateteres de inserção percutânea (CIP). A idade gestacional média dos RN foi 30,4 semanas (DP±3,89s), o peso ao nascer médio 1380,03 g (DP±742,68 g), com 76,03% de RN com muito baixo peso. O tempo de permanência médio dos CC foi 11,51 dias (DP±11,08 d). Obtivemos95 culturas positivas da ponta do CC, 25 (26,32%) de CU e 70 (73,68%) de CIP. De 41 hemoculturas colhidas, 9 foram positivas (21,95%), 2 de RN com CU e 7 de RN com CIP. Os Staphylococcus coagulase-negativos foram os micro-organismos mais frequentemente identificados. A taxa de infeção associada ao uso de CC foi 0,5%. A densidade de incidência de contaminação de CC foi 20,43/1000 dias de CC.DISCUSSÃO: Comparativamente ao estudo de 2011, verifica-se uma melhoria significativa na taxa de infeção associada ao uso de CC. A taxa de infeção e os agentes patogénicos identificados são semelhantes aos de outros estudos publicados.

Púrpura de Henoch-Schönlein Bolhosa: Caso Clínico

INTRODUÇÃO: A púrpura de Henoch-Schönlein (PHS) caracteriza-se por púrpura palpável associada a dor abdominal, artralgia ou atingimento renal. A variante bolhosa é rara em pediatria, geralmente com bom prognóstico.CASO CLÍNICO: Menino de 3 anos e 8 meses com febre e lesões purpúricas que evoluíram para púrpura palpável e edema tibiotársico bilateral com limitação da marcha. Por persistência de febre, agravamento das lesões cutâneas com aparecimento de vesículas, bolhas purpúricas e ulcerações, edema articular com incapacidade para a marcha e para ortostatismo e dor abdominal, foi reavaliado no serviço de urgência. Analiticamente proteína C reativa 29 mg/L e albumina 3 g/dL, sem outras alterações. Decidido internamento sob amoxicilina/ácido clavulânico e metilprednisolona. Apresentou boa evolução clínica, mantendo lesões cicatriciais e manchas hiperpigmentadas.DISCUSSÃO: A púrpura de Henoch-Schönlein bolhosa é rara em idade pediátrica e um desafio diagnóstico. A corticoterapia pode ser benéfica em alguns casos, sendo necessários mais estudos que corroborem a sua utilização. Na generalidade dos casos tem bom prognóstico.

Follow-up of infants born to mothers with Graves' disease

INTRODUCTION

The prevalence of neonatal hyperthyroidism (HN) due to maternal Graves Disease (GD) ranges from 0.1 to 2.7%. It may occur in pregnant women with the following: active DG, after treatment with radioactive iodine, anti-thyroid or thyroidectomy or with a previous child with hyperthyroidism. The aim of our observational study was to evaluate the follow-up of infants born to mothers with GD at a Tertiary Hospital prior to the implementation of a follow-up protocol.

METHODS

This was a retrospective observational study using data from the medical records of mothers with a diagnosis of GD and their newborns from January 2013 until May 2018. Newborns were divided into two groups: high and low risk for NH according to maternal TRAb, third trimester treatment and signs of fetal hyperthyroidism.

RESULTS

We identified 31 newborns, 58% female; 87% high risk. In none of the newborns was umbilical cord blood collected. In the high risk group, 22% had thyroid function evaluation at day-1, one patient presented with hyperthyroidism and 82% were asymptomatic. Considering the cases with an insufficient blood sample for analysis, 9 consultations would have been spared. We found a significant delay in obtaining the high-risk group results which would have spared 10 appointments. A positive correlation was found between age at outpatient clinic discharge and the number of appointments and the maternal TRAb titer.

CONCLUSION

The correct surveillance of pregnancy and newborns with identification of those at high risk is essential to avoid unnecessary consultations and blood analyses that increase parental anxiety and hospital costs. Consequently, a multidisciplinary protocol was created to standardize the approach.

SEOM clinical guidelines for cervical cancer (2019)

Cervical cancer (CC) is the fourth most common cancer in women worldwide, strongly linked to high-risk human papilloma virus infection. In high-income countries, the screening programs have dramatically decreased the incidence of CC; however, the lack of accessibility to them in developing countries makes CC an important cause of mortality. Clinical stage is the most relevant prognostic factor in CC. The new FIGO staging system published in 2018 is more accurate than the previous one since it takes into account the lymph node status. In early stages, the primary treatment is surgery-with some concerns recently raised regarding minimally invasive surgery because it might decrease survival-or radiotherapy, whereas concomitant chemo-radiotherapy is the conventional approach in locally advanced stages. For recurrent or metastatic CC, the combination of chemotherapy plus bevacizumab is the preferred therapy. Immunotherapy approach based on checkpoint inhibitors is evolving as the election therapy following failure to platinum therapy.

Analysis of competing risks of causes of death and their variation over different time periods in Hodgkin disease

18528

Background: Hodgkin’s disease is put forward as a model of curable illness. However, long-term studies show an excessive mortality in relation to the general population. The only way for detecting these causes are the long-term follow-up clinical studies, even these long-term follow-ups may not be fully representative of current causes of death. Methods: All patients diagnosed with HD at the University Hospital “Clínica Puerta de Hierro” between 1967 and 2003 were included. The competing risks of causes of death and the vital situation were examined in three time periods. Three cohorts were compared: cohort A with patients treated before 1980, B with those treated 1981–1986 and C from 1986 on. Results: We studied 534 patients, with a median follow-up time of 9.1 years for the whole cohort. The 5, 15 and 20-year Kaplan-Meier survival estimates for all patients were 81%, 72% and 65%, respectively. At the close of the study, 337 (63.1%) were alive and 170 (31.8%) had died. In general, the most common cause was the progress of Hodgkin’s disease, followed by deaths due to a second tumor. By time periods, we found statistically significant differences between cohort A and the other two cohorts, with less LD and MC histology, fewer advanced stages and fewer combined treatments in the latter. Between cohorts B and C there were only differences in the histological results, with less LD and MC and increased NS in the latter. Survival was significantly worse in the first period than in the other two (p<0.001) and in the three periods the main cause of death was tumor progression. Conclusions: The progression of Hodgkin’s disease is the main cause of death in all the periods studied. Over time a clear reduction in death related to the toxicity of treatments was seen. In the light of our results, the question is posed as to whether the survival and causes of death series for those patients treated since the 1970s are telling us about a real situation. Patients die now for reasons that are different from in the 1970s and this is important when planning preventive and clinical research activity.

No significant financial relationships to disclose.